The GIFDL-2 delivers a precisely calibrated galvanic current payload through a focused electrolytic carrier beam, driving rapid osmotic imbalance in the interstitial fluid of exposed soft tissue. The effect is a sudden, painful redistribution of fluid across cellular membranes in the targeted region — subcutaneous swelling, intense pressure sensation, and temporary loss of fine motor control as nerves compress against distended tissue. At high settings, capillary rupture produces visible bruising within minutes of exposure.

The lance's distinctive feature is its dual-mode emitter: a narrow 'focal' mode that concentrates the effect on a single limb or joint, and a wide 'flood' mode that distributes a milder osmotic disruption across the upper torso. Focal mode is the preferred surgical option for restraint operations — a single discharge to the hand renders grip impossible for up to forty minutes. Flood mode is used for area denial and crowd compliance, producing widespread discomfort without targeting specific anatomy.

Helix Biosystems developed the GIFDL-2 ostensibly for advanced surgical irrigation research, and the cover story has worn increasingly thin over the years. The weapon's design files were subpoenaed in two separate municipal investigations before Helix successfully argued proprietary protection. It remains technically legal in four of GLMZ's administrative sectors under a medical research exemption that no independent body has reviewed in over a decade.